PRC
AMAG

Pearl River Capital’s AMAG Pharmaceuticals AMAG Stock Holding History

Pearl River Capital’s Portfolio AMAG Stock Details AMAG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-3,684
Closed -$48K – 520
2019
Q1 		$48K Buy
3,684
+1,873
+103% +$27.9K 0.12% 241
2018
Q4 		$28K Buy
+1,811
New +$34.5K 0.13% 207

Other funds holding AMAG

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Pearl River Capital's AMAG Position: Q2 2019 in Review

Pearl River Capital sold out of AMAG Pharmaceuticals (AMAG) in Q2 2019, closing a stake of 3,684 shares — an estimated $48K sold.

Pearl River Capital first reported a position in AMAG in Q4 2018 and held it in 2 quarters. The position peaked at $48K in Q1 2019. 170 funds tracked by Wall St. Rank hold AMAG as of Q2 2019.

  • Pearl River Capital reported no remaining AMAG Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Pearl River Capital sold 3,684 AMAG Pharmaceuticals shares in Q2 2019, an estimated $48K.
  • Pearl River Capital first reported a position in AMAG Pharmaceuticals in Q4 2018 and held it in 2 quarters.
  • Pearl River Capital's AMAG Pharmaceuticals position peaked at $48K in Q1 2019.
  • 170 funds tracked by Wall St. Rank held AMAG Pharmaceuticals as of Q2 2019.

Based on Pearl River Capital's 13F filing for Q2 2019, filed 12 Aug 2019.